Coping With Somatic Comorbidities: Striving for Complete Recovery
By Christer Allgulander, MD, and Siegfried Kasper, MD
-
Optimizing Treatment Outcomes for Patients With Depression and Generalized Anxiety Disorder
By Michael E. Thase, MD, and Madhukar Trivedi, MD
-
Long-Term Treatment Strategies in Anxiety Disorders
By Christer Allgulander, MD, Robert M. A. Hirschfeld, MD, and David J. Nutt, MD, PhD
-
Generalized Anxiety Disorder: Raising the Expectations of Treatment
By Christer Allgulander, MD, and David V. Sheehan, MD, MBA
-
New Developments in the Neurobiological Basis of Anxiety Disorders
By Jack M. Gorman, MD, Robert M. A. Hirschfeld, MD, and Philip T. Ninan, MD
-
Long-Term Treatment Strategies in Affective Disorders
By Martin B. Keller, MD
-
New Goals in the Treatment of Depression: Moving Toward Recovery By Michael E. Thase, MD, and Philip T. Ninan, MD By Michael E. Thase, MD, and Philip T. Ninan, MD -
Recent Advances in the Neurobiology of Depression
By Charles B. Nemeroff, MD, PhD
-
Remission: Today’s Target in the Treatment of Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
-
Comparing the Methods Used to Compare Antidepressants
By Michael E. Thase, MD
-
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
-
Intermittent Fluoxetine Dosing in the Treatment of Women With Premenstrual Dysphoria
By Meir Steiner, MD, PhD, FRCPC, Marilyn Korzekwa, MD, FRCPC, John Lamont, MD, MSc, FRCSC, and Annette Wilkins, BA
-
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By Lindsay DeVane, PharmD
-
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
-
A Discussion on the Methodologies Used to Evaluate Antidepressants
MODERATOR: Jan A. Fawcett, MD
DISCUSSANTS: Norman Sussman, MD Jeffrey H. Newcorn, MD
-
Risperidone: Review of Its Therapeutic Utility in Depression
By Joyce E. Myers, MD, and Michael E. Thase, MD
-
A Model to Explain the Therapeutic Effects of Serotonin Reuptake Inhibitors: The Role of 5-HT2 Receptors
By Mikael Landén, MD, PhD, and Michael E. Thase, MD
-
Treatment of Children with Attention-Deficit/Hyperactivity Disorder: Results of a Randomized, Multicenter, Double-Blind, Crossover Study of Extended-Release Dexmethylphenidate and D,L-Methylphenidate and Placebo in a Laboratory Classroom Setting
By Raul Silva, MD, Rafael Muniz, MD, Kevin McCague, MA, Ann Childress, MD, Matthew Brams, MD, and Alice Mao, MD
-
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
By Robert R. Conley, MD and Deanna L. Kelly, PharmD, BCPP
-
Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale
By Larry Alphs, MD, PhD, John Panagides, PhD, and Scott Lancaster, MS
-
Does Isotretinoin Cause Depression and Suicide?
By J. Douglas Bremner, MD
-
Anxiety and Other Emotional Factors in Noncardiac Chest Pain
By Kamila S. White, PhD and Susan D. Raffa, MA
-
Recognition and Treatment of Anxiety Disorders in Primary Care
By Risa B. Weisberg, PhD and Kristin M. Maki, PhD
-
Panic Disorder During Pregnancy
By Dana March, BA and Kimberly A. Yonkers, MD
-
Economic Impacts of Anxiety Disorders
By Ernst R. Berndt, PhD and Tamar Sisitsky, MA
-
Anxiety Disorders
Overview:
Vast Progress but a Long Journey Ahead
By Tracey M. Boudine
-
Cause & Effect
Dealing with the Loss of a Spouse
By Dina Kerasiotis, RN, PsyD
-
The MentalFitness Interview: David Shaffer, FRCP, FRCPsych, on the Rise and Fall of the Teen Suicide Rate -
Psychiatric Bulletin:
Late-Breaking Clinical News
-
Efficacy of Combined Pharmacological and Cognitive- Behavioral Treatments For Anxiety Disorders
By Steven E. Bruce, PhD and Kamila S. White, PhD
-
Gender and Schizophrenia
By Carla M. Canuso, MD and Gahan Pandina, PhD
-
Genetics of Schizophrenia: Recent Advances
By Amy Eisener, BS, Michele T. Pato, MD, Helena Medeiros, MSW, Celia Carvalho, MS, and Carlos N. Pato, MD
-
Neuropsychiatric Update: Neuroimaging Schizophrenia
By Shawn J. Kile, MD
-
Ethical Issues In Schizophrenia: Considerations for Treatment and Research
By Laura B. Dunn, MD
